Nikhil Lalwani

President and Chief Executive Officer, ANI Pharmaceuticals

Princeton, New Jersey

About

Nikhil Lalwani is President and Chief Executive Officer of ANI Pharmaceuticals, Inc., and a member of its board of directors. ANI is a bio-pharmaceutical company based in Princeton, New Jersey, that develops, manufactures and commercializes therapeutics through its Rare Disease, Generics and Other, and Brands businesses. Lalwani has led the company since September 2020.

Before ANI he was Chief Executive Officer of the India Rx Business at Cipla from April 2017 to April 2020, and he also served as CEO of Cipla USA from April 2017 to April 2020 and of InvaGen, a Cipla subsidiary, from April 2016 to April 2020. Earlier he worked as an Associate Partner at McKinsey & Company and as an engineer at Medtronic. He holds a B.S. in Electrical Engineering from the Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania. Other pharmaceutical leaders with pages on Whoo include David Ricks and Albert Bourla.

Whoo compiled this page from public sources: ANI Pharmaceuticals 2026 proxy statement (SEC), ANI Pharmaceuticals Form 10-K (SEC), ANI Pharmaceuticals Form 10-Q, September 2026 (SEC). It is not affiliated with or endorsed by Nikhil Lalwani. Are you Nikhil Lalwani? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

President and Chief Executive Officer — ANI Pharmaceuticals


September 2020 – Present | Princeton, New Jersey

Chief Executive Officer, India Rx Business — Cipla


April 2017 – April 2020

Chief Executive Officer — Cipla USA and InvaGen


Cipla USA: April 2017 – April 2020; InvaGen: April 2016 – April 2020

Associate Partner — McKinsey & Company

Engineer — Medtronic

Education

M.B.A. — Wharton School, University of Pennsylvania

B.S. in Electrical Engineering — Georgia Institute of Technology

Projects